Next Generation Physicians are Using Augmented Intelligence: Is the Law Ready?
What if a physician working alone at night in a rural hospital could summon a tireless “Dr. House” with every difficult case; a trained medical diagnostician that is always awake, ever ready, and rarely hallucinates? Interactive artificial intelligence (AI) diagnostic models are rapidly evolving beyond ChatGPT and traditional “black box” […]
340b Rebate: Essential for Under-Resourced Hospitals or a Hinderance to Pharmaceutical Companies?
Earlier this month, the United States Court of Appeals for the First Circuit issued a Rule 42 motion to voluntarily dismiss a case filed by the American Hospital Association (AHA) against Robert F. Kennedy Jr. and the Health Resources and Services Agency (HRSA) regarding the implementation of a new pilot […]
Conversion Therapy on Trial: What Chiles v. Salazar Means for Medical Regulation and LGBTQ+ Protections
The Supreme Court heard arguments on October 7, 2025 to lift Colorado’s ban on “conversion therapy,” a discredited practice which targets LGBTQ+ youth to change their sexual orientation or gender identity. In Chiles v. Salazar, Kaley Chiles, a Colorado-licensed professional counselor, challenged a Colorado state regulation which prohibits providers from […]
Does Trump’s Call For Expanding IVF Access Have Any Real Legal Teeth?
Assistance with fertility care is an urgent need for many families across the United States. According to findings from the 2024 Kaiser Family Foundation(KFF) Women’s Health Survey, one in eight reproductive-age women said that they or their partner needed fertility services to help them become pregnant or prevent a miscarriage. […]
The Patent Thicket Just Got Thicker: Limiting Inter Partes Review for Biologic Drug Patents
While a best-selling small molecule drug could be covered by up to five patents, biologic drugs (large chemical compounds produced by living cells) are covered by hundreds of patents. A primary purpose of patents is to give a limited monopoly to inventors to incentivize innovation, but this monopoly comes at […]
